Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well.. @RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ